Pfizer Inc. (PFE)
Healthcare · end-of-day data as of Oct 16, 2026
The average 12-month analyst price target for PFE is $27.49, 7.1% below the last close of $29.58 on Oct 16, 2026; targets range from $24.17 to $33.24. Rating consensus: Hold.
Snapshot
- P/E39.1x
- P/E vs sector+38.8%
- P/E vs own+84.3%
- Target upside-7.1%
- ConsensusHold
- Market cap$169B
- FCF yield+6.5%
- Insiders$2.88M
- Earnings in18d
- News
Why it moved
Pfizer Inc. (PFE) rose 0.5% on Oct 16, 2026.
The market (SPY) fell 1.1%; Healthcare stocks fell 0.7%. Most of the move is specific to PFE.
4 stories on the day (30-day average 4.0).
- Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe?
- Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady
- Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.
Price and events
Last close $29.58 · +30.7% over 1y · E earnings · D dividend · S split · A analyst rating change
Technicals
- Trendbullish
- Sector▲ +16.0%
- MAs20▲ 50▲ 100▲ 200▲
- Above MAs4 of 4 above
- MA20×50—
- RSI70
- Support-3.3%
- Resistance—
- Off 52w high0.0%
- Off ATH-37.6%
- 52w range$29.58
- Bollingerabove upper
- MACD0.13
- ATR+1.9%
- Volume0.9x
Analyst price targets
13 firms with a target in the last 12 months · last close $29.58 · as of Oct 16, 2026
Strong buy 2 · Buy 8 · Hold 16 · Sell 1 · Strong sell 1
Revenue and free cash flow
Q2 FY2026: Revenue +2.6% year over year, free cash flow 2.0% of revenue, operating margin 31.3%.
| Q2 FY2026 | Jun 28, 2026 | $15.03B | -0.04 | $302M | 72.8% | 31.3% | -1.6% |
| Q1 FY2026 | Mar 29, 2026 | $14.45B | 0.47 | $2.18B | 67.3% | 27.9% | 18.6% |
| Q4 FY2025 | Dec 31, 2025 | $17.56B | -0.29 | $4.5B | 70.0% | 21.0% | -9.4% |
| Q3 FY2025 | Sep 28, 2025 | $16.65B | 0.62 | $4B | 74.9% | 21.3% | 21.3% |
| Q2 FY2025 | Jun 29, 2025 | $14.65B | 0.51 | -$1.2B | 64.3% | 24.4% | 19.9% |
| Q1 FY2025 | Mar 30, 2025 | $13.71B | 0.52 | $1.77B | 71.7% | 33.7% | 21.6% |
| Q4 FY2024 | Dec 31, 2024 | $17.76B | 0.07 | $5.8B | 73.0% | 32.2% | 2.3% |
| Q3 FY2024 | Sep 29, 2024 | $17.7B | 0.78 | $6.06B | 60.8% | 28.1% | 25.3% |
Peers
| 20D | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 |  | $255.56 | +0.9% | -8.2% | +8.8% | 38.7 | $616B | |
| 2 |  | $285.42 | +0.7% | 0.0% | -1.4% | 80.4 | $504B | |
| 3 |  | $145.95 | +0.5% | -6.2% | +7.7% | 116.8 | $360B | |
| 4 |  | $432.49 | -0.4% | -2.6% | -7.5% | 26.9 | $234B | |
| 5 |  | $156.19 | -0.7% | -0.7% | +1.9% | — | $194B | |
| 6 | | $29.58 | +0.5% | 0.0% | -7.1% | 39.1 | $169B | |
| 7 |  | $59.75 | -1.4% | -11.3% | +9.4% | 13.2 | $122B | |
| 8 |  | $232.65 | -1.1% | -1.1% | +2.7% | 41.2 | $34.37B |
Data as of Oct 16, 2026 close.
Latest news
Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.